Emgality (galcanezumab) arrived as the third CGRP antibody for migraine prevention, joining Aimovig and Ajovy. Like Ajovy, it works by capturing CGRP molecules directly - binding them before they can reach pain receptors in the trigeminal system. But Emgality has its own pharmacological profile, its own dosing strategy, and its own set of reasons it may not work for you.
It's also the only CGRP antibody with FDA approval for episodic cluster headache - a detail that reveals something about how aggressively it suppresses CGRP in certain vascular territories. That same pharmacology is why it works brilliantly for some migraine patients and does almost nothing for others.
If Emgality isn't working for you, there are several Emgality-specific factors to rule out before concluding that the drug has failed - and several things its failure tells you about where your migraines actually live.
Before you give up on Emgality
Two of the most common reasons Emgality "fails" are fixable: a skipped loading dose and an evaluation window that was too short. Make sure both were done correctly before writing off the medication entirely.
The Loading Dose Problem
Emgality is the only CGRP antibody that uses a true loading dose. The FDA-approved protocol starts with 240mg - two separate 120mg injections administered on the same day - followed by 120mg once monthly. That first double dose exists for a reason: it floods the system with antibodies to rapidly bind circulating CGRP, getting suppression to effective levels within the first month rather than building up slowly over two or three cycles.
Some providers skip the loading dose. This happens for various reasons - insurance restrictions, concern about injection site reactions, or simply not following the full protocol. Patients who start at 120mg instead of 240mg begin with roughly half the CGRP suppression they should have, and it takes longer to reach the steady-state levels that the clinical trials were built around.
Check your start
If you received only one injection on your first visit, you didn't get the loading dose. This doesn't mean Emgality can't work for you - but it means your first month of data isn't representative of what the drug actually does at full saturation. Ask your provider whether restarting with the proper loading dose is an option before concluding the medication failed.
The 3-Month Evaluation Window
CGRP antibodies don't work like triptans or pain relievers. You don't take them and feel the effect within hours. They work by gradually reducing CGRP-driven sensitization across the trigeminal system - and that process takes time.
The consensus among headache specialists is that you need at least 3 full monthly injection cycles before properly evaluating whether a CGRP antibody is effective. Here's why the timeline matters:
Month 1: Antibody levels build (faster with loading dose). Some patients notice improvement, but many don't. The nervous system is still running on its pre-treatment pattern.
Month 2: Steady-state antibody levels are approaching their target. The trigeminal system has been under sustained CGRP suppression for several weeks. Some patients begin responding here.
Month 3: Full evaluation point. The nervous system has had enough time under continuous CGRP blockade for sensitized pathways to begin resetting. If there's no meaningful change by now, CGRP suppression alone is likely insufficient.
Many patients - and even some providers - give up after one or two months. This is particularly common when the loading dose was skipped, creating a situation where the drug never reached proper levels before the trial was abandoned. If you stopped before month 3, Emgality didn't get a complete evaluation.
What Injection Site Reactions Tell You
Emgality has notably higher injection site reaction rates than Aimovig or Ajovy. Redness, itching, swelling, and hardened lumps at the injection site are reported more frequently with galcanezumab - and for some patients, these reactions are severe enough to make continuing the medication difficult.
But injection site reactions aren't just an inconvenience to tolerate. They're an immune signal worth paying attention to.
The mast cell connection
Persistent, exaggerated injection site reactions can suggest heightened mast cell reactivity. Mast cells are immune cells that release histamine when activated - and histamine is itself a potent migraine trigger operating through an entirely different pathway than CGRP.
If your injection sites stay red, swollen, or itchy for days after each dose, it may be worth investigating whether histamine-driven pathways are contributing to your migraines. A drug that blocks CGRP won't address histamine-mediated attacks - and your body's strong reaction to the injection itself may be pointing you toward the actual driver.
Emgality With Other Migraine Medications
One of Emgality's practical advantages is that it has very few drug interactions. As a monoclonal antibody, it doesn't pass through the liver's cytochrome P450 system, so it doesn't interfere with most other medications. You can generally take it alongside beta-blockers, antidepressants, anticonvulsants, and other preventives without pharmacological conflict.
The one combination that gets theoretical attention is Emgality plus triptans. Both reduce CGRP-mediated vasodilation - Emgality by capturing CGRP molecules, triptans by constricting blood vessels through serotonin receptors. In theory, this creates a scenario where two different mechanisms are both reducing blood vessel dilation simultaneously. In practice, this combination is widely used and has not produced significant safety signals in clinical data.
The more important question
If you're on Emgality for prevention and still need triptans regularly for breakthrough attacks, that combination is telling you something. A CGRP antibody providing round-the-clock CGRP suppression should substantially reduce migraine frequency if CGRP is the main driver. If you still need acute treatment frequently, your migraines likely have multiple active pathways - CGRP may be one input, but histamine, hormonal shifts, or threshold instability may be doing equal or greater work.
When Emgality Does Work
Understanding who responds well to Emgality helps clarify why it may not be working for you. The patients who tend to see the strongest results share certain patterns:
Cluster headache overlap
Emgality's FDA approval for episodic cluster headache isn't coincidental. Patients whose migraines share features with cluster patterns - unilateral, severe, with autonomic symptoms like tearing or nasal congestion on one side - may have CGRP-dominant neurovascular activation that galcanezumab is particularly suited to suppress.
High-frequency episodic migraine
Patients with 8-14 migraine days per month - the upper end of episodic migraine - often respond well. This frequency range suggests enough CGRP pathway activation to benefit from sustained blockade, but not so much chronification that central sensitization has taken over.
Classic CGRP-driven patterns
Migraines with prominent throbbing or pulsating quality, significant photophobia, nausea that tracks with headache intensity, and clear onset-to-peak-to-resolution phases. These features suggest vascular and trigeminal CGRP signaling is doing most of the work - exactly what Emgality targets.
No major comorbid drivers
Patients without significant histamine sensitivity, hormonal instability, autonomic dysfunction, or medication overuse tend to respond better - because CGRP is operating without competition from other active pathways.
If your migraine pattern doesn't match these profiles, it doesn't mean you can't respond to Emgality - but it does suggest other pathways may be more active than CGRP in your system.
What Emgality Failure Actually Reveals
If you've done a proper Emgality trial - loading dose, three full months, consistent administration - and your migraines haven't meaningfully improved, that's not a dead end. It's a significant piece of diagnostic information.
Emgality provides aggressive, sustained CGRP molecule capture - 24 hours a day, 7 days a week, for a full month. If that level of CGRP suppression doesn't change your migraine pattern, CGRP is very likely not the dominant driver. The system is under pressure somewhere else.
Where else? Histamine pathways are the most common alternative driver that CGRP therapies miss entirely. Hormonal instability, autonomic dysfunction, and vascular underfill are others. Each medication failure narrows the search - and Emgality failure narrows it substantially by ruling out peripheral CGRP as the main input. That's progress, even when it doesn't feel like it.
What to Discuss With Your Clinician
- • Whether you received the full 240mg loading dose - and if not, whether restarting with it is appropriate
- • Whether you completed at least 3 full monthly cycles before evaluating effectiveness
- • Whether switching to Aimovig (receptor blocker) could produce a different result, since it works through a different mechanism than Emgality's molecule capture
- • Whether persistent injection site reactions suggest mast cell or histamine involvement worth investigating
- • Whether a gepant like Nurtec could work differently by crossing the blood-brain barrier to reach central CGRP pathways
- • Whether investigating non-CGRP pathways - histamine, hormonal, autonomic - could identify the actual dominant driver
This guide is for education and pattern-recognition only. It is not medical advice and is not a plan to start, stop, or change any medication, supplement, or test. Always discuss treatment decisions with a licensed clinician who knows your history.
Clinical and Review Articles
- Stauffer VL et al. Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial. JAMA Neurology. 2018;75(9):1080-1088.
- Skljarevski V et al. Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 Phase 3 randomized controlled clinical trial. Cephalalgia. 2018;38(8):1442-1454.
- Detke HC et al. Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology. 2018;91(24):e2211-e2221.
- Goadsby PJ et al. Trial of galcanezumab in prevention of episodic cluster headache. New England Journal of Medicine. 2019;381(2):132-141.
- Edvinsson L. The trigeminovascular pathway: role of CGRP and CGRP receptors in migraine. Headache. 2017;57(S2):47-55.
Already have test results?
If you've accumulated years of normal tests but still have migraines, those records may contain patterns that haven't been examined together.
Related reading
This is educational content, not medical advice. Always consult a qualified clinician.